Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>

The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.

Inclusion Criteria:

• Patients who are considered by the investigator eligible for the present study with no significant safety concerns
• Patients who are fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion Criteria:

• Patients who are planning pregnancy for the expected duration of the study
• Patients who are otherwise considered ineligible for the study by the investigator